Manufacturing, Vaccines

Samsung Biologics to Construct New Manufacturing Facility for Next-Gen Vaccines and CGT

January 18, 2022

Samsung Biologics is planning to construct a new manufacturing facility in Incheon, South Korea, that will offer multi-product manufacturing, including cell and gene therapies and next-gen vaccines.

Sustainable Shippers for Ultra-Cold Conditions

January 17, 2022

Protective external packaging ensures COVID-19 vaccines arrive safely.

Merck KGaA Acquires CDMO Exelead

January 11, 2022

The agreeement will add to Merck KGaA’s LNP and mRNA capabilities.

Pfizer and Acuitas Therapeutics Collaborate on Lipid Nanoparticle Delivery System

January 11, 2022

The agreement expands Pfizer’s access to LNP formulation technology for mRNA vaccines and therapeutics.

Piramal Pharma Invests Minority Stake in India-Based CDMO, Yapan Bio

January 05, 2022

With this investment into Yapan Bio, Piramal Pharma adds new technologies and capabilities in large molecules, including vaccines and gene therapies, to its global offering.

Fareva and ApiJect Plan Vaccine Packaging Capacity in France

December 13, 2021

Fareva plans to use blow-fill-seal equipment and ApiJect’s prefilled injector technology to create fill/finish capacity in France.

Sanofi to Acquire Origimm Biotechnology for Vaccine-based Acne Treatment

December 09, 2021

Sanofi’s acquisition of Origimm Biotechnology will add to its pipeline of vaccine candidates for treating acne.

Accelerating Project Delivery with a Lean Alternative to DBB

December 02, 2021

Lean delivery offers a promising solution to supply and manufacturing bottlenecks by integrating project teams early on and widening the team’s field of view.

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp to Build mRNA Vaccine Manufacturing Capacity

November 29, 2021

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp. have partnered to advance GreenLight’s mRNA COVID-19 vaccine candidate.

Vaccine Makers Seek to Address Omicron SARS-CoV-2 Variant

November 29, 2021

The companies are testing their existing vaccines against the new variant of concern and are pursuing variant-specific versions.